NCT03983993 2026-01-05
NIPAVect
Emory University
Phase 2 Active not recruiting
Clinical Trials
35 trialsNCT01312857 2025-10-09
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03263429 2024-08-30
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT00788957 2024-08-07
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NantBioScience, Inc.
Phase 1/2 Completed
NCT00891930 2024-07-17
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NantBioScience, Inc.
Phase 2 Completed
NCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT01776307 2023-11-15
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Sumitomo Pharma America, Inc.
Phase 2 Completed
NCT02394795 2023-11-01
PARADIGM
Takeda
Phase 3 Completed
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT01732783 2022-11-08
Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients
Amgen
Completed
NCT00089635 2022-11-07
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
Amgen
Phase 2 Completed
NCT00113763 2022-11-07
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00364013 2022-11-07
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Amgen
Phase 3 Completed
NCT01001377 2022-09-21
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT02448810 2021-05-25
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Takeda
Phase 2 Terminated
NCT01504477 2020-03-16
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Georgetown University
Phase 1/2 Terminated
NCT01057017 2020-02-17
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Brown University
Phase 2 Terminated
NCT00508404 2019-11-19
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
Amgen
Phase 2 Completed
NCT02337946 2019-09-10
SAPPHIRE
Takeda
Phase 2 Completed
NCT00940316 2019-05-07
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
Phase 2 Completed
NCT00115765 2018-10-17
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Amgen
Phase 3 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT02508077 2018-08-16
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT00842257 2017-05-16
Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT02089737 2017-04-06
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
Takeda
Completed
NCT01412957 2017-03-15
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00563316 2016-04-12
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Amgen
Phase 1 Completed
NCT00332163 2016-02-23
STEPP
Amgen
Phase 2 Completed
NCT00411450 2016-02-15
PRECEPT
Amgen
Phase 2 Completed
NCT01226719 2015-05-27
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00630786 2014-02-06
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Amgen
Phase 1/2 Completed
NCT00083616 2014-01-10
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
Amgen
Phase 2 Completed
NCT00111761 2013-12-12
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
Amgen
Phase 2 Completed